1402063-05-1

Basic information

• Product Name: 2-(4-(ethyl(methyl)amino)benzylidene)-6-hydroxy-5-methoxy-2,3-dihydro-1H-inden-1-one hydrochloride
• Synonyms: 2-(4-(ethyl(methyl)amino)benzylidene)-6-hydroxy-5-methoxy-2,3-dihydro-1H-inden-1-one hydrochloride
• CAS NO: 1402063-05-1
• Molecular Weight: 359.853
• Mol File: 1402063-05-1.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 2-(4-(ethyl(methyl)amino)benzylidene)-6-hydroxy-5-methoxy-2,3-dihydro-1H-inden-1-one hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-(ethyl(methyl)amino)benzylidene)-6-hydroxy-5-methoxy-2,3-dihydro-1H-inden-1-one hydrochloride(1402063-05-1)
• EPA Substance Registry System: 2-(4-(ethyl(methyl)amino)benzylidene)-6-hydroxy-5-methoxy-2,3-dihydro-1H-inden-1-one hydrochloride(1402063-05-1)

Safety Data

• Hazardous Substances Data: 1402063-05-1(Hazardous Substances Data)

Upstream product

• 79865-89-7 4-(ethylamino)benzaldehyde 
• 459-57-4 4-fluorobenzaldehyde 
• 90843-62-2 6-hydroxy-5-methoxyindan-1-one 
• 124702-80-3 5,6-dihydroxy-indan-1-one 
• 2107-69-9 5,6-dimethoxy-1-indanone 
• 1402062-93-4 C₁₅H₁₈O₄ 
• 64693-47-6 4-(ethyl(methyl)amino)benzaldehyde 

Relevant articles and documents

Multitarget-directed benzylideneindanone derivatives: Anti-β-amyloid (Aβ) aggregation, antioxidant, metal chelation, and monoamine oxidase B (MAO-B) inhibition properties against Alzheimer's disease

A novel series of benzylideneindanone derivatives were designed, synthesized, and evaluated as multitarget-directed ligands against Alzheimer's disease. The in vitro studies showed that most of the molecules exhibited a significant ability to inhibit self-induced β-amyloid (Aβ 1-42) aggregation (10.5-80.1%, 20 μM) and MAO-B activity (IC 50 of 7.5-40.5 μM), to act as potential antioxidants (ORAC-FL value of 2.75-9.37), and to function as metal chelators. In particular, compound 41 had the greatest ability to inhibit Aβ1-42 aggregation (80.1%), and MAO-B (IC50 = 7.5 μM) was also an excellent antioxidant and metal chelator. Moreover, it is capable of inhibiting Cu(II)-induced Aβ1-42 aggregation and disassembling the well-structured Aβ fibrils. These results indicated that compound 41 is an excellent multifunctional agent for the treatment of AD.